welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals in Collaboration with the NCI and Vanderbilt University Medical Center Initiates Phase 2 Trial to Evaluate CPP-1X in Patients with High Risk of Gastric Cancer
Cancer Prevention Pharmaceuticals, Inc. (“CPP”) announced today the launch of a Phase 2 clinical trial at Vanderbilt University Medical Center to evaluate CPP-1X in patients with precancerous gastric lesions who are at high risk for gastric cancer.
The trial is funded by the National Cancer Institute (NCI) and run in collaboration with Keith T. Wilson, M.D., and Douglas R. Morgan, M.D., MPH, of Vanderbilt University School of Medicine, Vanderbilt University Medical Center, and the Vanderbilt-Ingram Cancer Center.
expertly curated content related to this topic
-
Meta-Analysis of Observational Studies of Ileorectal Versus Ileal Pouch-Anal Anastomosis for Familial Adenomatous Po...BACKGROUND : Surgery for familial adenom...
-
Congenital Hypertrophy Retinal Pigment Epithelium as a Manifestation of Colon CancerCongenital hypertrophy retinal pigment e...
-
Food Fit for a Baby J-pouch: The Early Post-Proctocolectomy Diet (the newest fad diet)https://www.youtube.com/watch?v=ms8o1BBN...
-
An Evaluation of SprayShield in Reducing Post-Operative Adhesion Formation Following Major Open Abdominal SurgeryThis will be a prospective, multi-center...
-
Single Incision Laparoscopic Surgery in Treating Patients With Colorectal DiseaseThis study is being done to evaluate sin...
-
Sulindac for Periampullary Polyps in FAP PatientsBACKGROUND : Gastro-duodenal polyps deve...
-
Food Fit for a J-Pouchhttps://www.youtube.com/watch?v=RxiYAWkx...